Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Otsuka Pharm Drug Patent Portfolio

Otsuka Pharm owns 1 orange book drug protected by 4 US patents Given below is the list of Otsuka Pharm's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5430057 Parenteral busulfan for treatment of malignant disease 30 Mar, 2014 Expired
US5559148 Parenteral busulfan for treatment of malignant disease 30 Mar, 2014 Expired
US5430057 Parenteral busulfan for treatment of malignant disease 30 Sep, 2013 Expired
US5559148 Parenteral busulfan for treatment of malignant disease 30 Sep, 2013 Expired


Otsuka Pharm's Family Patents


Family Patents





Clinical Trials

Recent Clinical Trials by Otsuka Pharm:

Title Lead Sponsor Collaborators Status Phases
Clinical Trials
Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia Otsuka Pharmaceutical Europe Ltd H. Lundbeck A/S UNKNOWN
(Apr, 2019)
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features. Otsuka Pharmaceutical Development & Commercialization, Inc. NA TERMINATED
(Jan, 2016)
PHASE3
Aripiprazole for the Augmentation of Antidepressant Therapy Taiwan Otsuka Pharm. Co., Ltd NA COMPLETED
(May, 2014)
PHASE4
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical COMPLETED
(Feb, 2013)
PHASE3
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia Otsuka Pharmaceutical Development & Commercialization, Inc. Otsuka America Pharmaceutical COMPLETED
(Aug, 2008)
PHASE4
Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders Otsuka Pharmaceutical Development & Commercialization, Inc. NA COMPLETED
(Sep, 2007)
PHASE2, PHASE3


Otsuka Pharm Drug List

Given below is the complete list of Otsuka Pharm's drugs and the patents protecting them.


1. Busulfex

Busulfex is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5430057
(Pediatric)
Parenteral busulfan for treatment of malignant disease 30 Mar, 2014
(11 years ago)
Expired
US5559148
(Pediatric)
Parenteral busulfan for treatment of malignant disease 30 Mar, 2014
(11 years ago)
Expired
US5430057 Parenteral busulfan for treatment of malignant disease 30 Sep, 2013
(11 years ago)
Expired
US5559148 Parenteral busulfan for treatment of malignant disease 30 Sep, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Busulfex's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List